CAMBRIDGE, Mass., Feb. 13, 2019 /PRNewswire/ -- TCR2
Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy
company developing the next generation of novel T cell receptor
(TCR) therapies for patients suffering from cancer, today announced
the pricing of the Company's initial public offering of 5,000,000
shares of common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of
$75.0 million, before deducting
underwriting discounts and commissions and offering expenses. The
Company has also granted the underwriters a 30-day option to
purchase from the Company up to an additional 750,000 shares of
common stock at the initial public offering price, less the
underwriting discounts and commissions. All of the shares are being
offered by TCR2.
The common stock is expected to begin trading on The Nasdaq
Global Select Market under the ticker symbol "TCRR" on February 14, 2019. The offering is expected to
close on February 19, 2019, subject
to customary closing conditions.
Jefferies, SVB Leerink and BMO Capital Markets are acting as
joint book-running managers for the offering. Wedbush PacGrow and
China Renaissance are acting as co-managers for the offering.
A registration statement relating to the shares being sold in
this offering was declared effective by the Securities and Exchange
Commission on February 13, 2019. The
offering of these shares is being made only by means of a
prospectus forming part of the effective registration statement
relating to these shares. Copies of the prospectus may be obtained
from: Jefferies LLC, Attention: Equity Syndicate Prospectus
Departments, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com; SVB
Leerink LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA,
02110, by e-mail at syndicate@svbleerink.com, or by phone at (800)
808-7525, ext. 6132; or BMO Capital Markets Corp., Attn: Equity
Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, tel: (800) 414-3627,
email: bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities law of such state or
jurisdiction.
About TCR2 Therapeutics
TCR2 is an
innovative immunotherapy company developing the next generation of
novel T cell receptor therapies for patients suffering from
cancer.
View original
content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-announces-pricing-of-initial-public-offering-of-common-stock-300795485.html
SOURCE TCR2 Therapeutics